CPRX Live signaler | Maksimer profitt med Getagraph.com

KJøP 106702 min ago

@ $13.37

Utstedt: 14 feb 2024 @ 20:08

Avkastning: 11.41%

Forrige signal: feb 13 - 16:35

Forrige signal: Selg

Avkastning: 0.00 %

Live Chart Being Loaded With Signals

Commentary (26 apr 2024 @ 22:00):

Stats
Dagens volum	772 159
Gjennomsnittsvolum	1.34M
Markedsverdi	1.75B
EPS	$0 ( 2024-03-20 )
Neste inntjeningsdato	( $0.340 ) 2024-05-08
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	23.63
ATR14	$0.00800 (0.05%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-08	Tierney David S	Buy	25 000	Common stock, par value $0.001 per share
2024-04-08	Tierney David S	Sell	25 000	Common stock, par value $0.001 per share
2024-04-08	Tierney David S	Buy	25 000	Options to purchase common stock
2024-03-27	Elsbernd Brian	Sell	25 000	Common stock, par value $0.001 per share
2024-02-15	Del Carmen Jeffrey	Sell	10 667	Restricted Stock Units

INSIDER POWER
37.04
Last 100 transactions
Buy: 3 182 900 \| Sell: 1 448 545

Volum Korrelasjon

Lang: -0.46 (neutral)

Kort: -0.52 (weak negative)

Signal:(47.337) Neutral

Catalyst Pharmaceuticals Korrelasjon

10 Mest positive korrelasjoner
PMTS	0.897
KPTI	0.88
AVID	0.873
PRAA	0.854
FCCO	0.852
BNIXU	0.849
PINC	0.848
KTCC	0.844
PARA	0.843
DTEA	0.838

10 Mest negative korrelasjoner
CVGI	-0.927
CRSP	-0.915
NNOX	-0.915
POWL	-0.914
ADMS	-0.914
FTDR	-0.912
MDXG	-0.912
FLGC	-0.905
CNCE	-0.905
RESN	-0.904

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Catalyst Pharmaceuticals Korrelasjon - Valuta/Råvare

-0.48
( neutral )

-0.30
( neutral )

0.00
( neutral )

-0.51
( weak negative )

0.00
( neutral )

0.77
( moderate )

Catalyst Pharmaceuticals Økonomi

Annual	2023
Omsetning:	$398.20M
Bruttogevinst:	$313.67M (78.77 %)
EPS:	$0.670

FY	2023
Omsetning:	$398.20M
Bruttogevinst:	$313.67M (78.77 %)
EPS:	$0.670

FY	2022
Omsetning:	$214.20M
Bruttogevinst:	$179.81M (83.94 %)
EPS:	$0.800

FY	2021
Omsetning:	$140.83M
Bruttogevinst:	$118.95M (84.46 %)
EPS:	$0.380

Financial Reports:

No articles found.

Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company also develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis, and spinal muscular atrophy type 3, as well as to treat hereditary neuropathy with liability to pressure palsies. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was formerly known as Catalyst Pharmaceutical Partners, Inc. and changed its name to Catalyst Pharmaceuticals, Inc. in May 2015. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.